Adicet Bio reports the dosing of the initial lupus nephritis patient in its Phase 1 trial of ADI-001 for autoimmune conditions.

Arrowhead Pharmaceuticals has filed a New Drug Application with the U.S. FDA for plozasiran to treat Familial Chylomicronemia Syndrome.

Seismic Therapeutics showcases new preclinical findings for S-4321, a next-gen bifunctional agonist antibody that targets PD-1 and FcγRIIb.

The trial tests TGN-S11 alone and in combination with Keytruda® (pembrolizumab) for stage 4 cancer patients associated with Human Papillomavirus.

Samsung Bioepis and Biogen have obtained approval from the European Commission (EC) for their Aflibercept biosimilar, named OPUVIZ.

Bluejay Therapeutics, has revealed new findings from its Phase 2 trial of BJT-778.

Acepodia has received FDA approval for the Investigational New Drug Application of ACE1831 to treat IgG4-related disease.

Syndax has received FDA approval for Revuforj® (revumenib), marking it as the first menin inhibitor for treating adults and children with relapsed or refractory acute leukemia featuring a KMT2A translocation.

InnoCare reports the initial dosing of a participant in China's Phase III trial of the TYK2 inhibitor ICP-332 for treating atopic dermatitis.

AC Immune Announces Favorable Preliminary Findings from Phase 2 Study of ACI-7104.056 Active Immunotherapy for Early Parkinson’s Disease.

Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Levicept Unveils Promising Phase II Results for LEVI-04, a New Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis at ACR Convergence 2024.